PT  - JOURNAL ARTICLE
AU  - Romain Bos
AU  - Nathalie Mougenot
AU  - Odile Médiani
AU  - Paul M. Vanhoutte
AU  - Philippe Lechat
TI  - Potassium Canrenoate, an Aldosterone Receptor Antagonist, Reduces Isoprenaline-Induced Cardiac Fibrosis in the Rat
AID  - 10.1124/jpet.103.063388
DP  - 2004 Jun 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 1160--1166
VI  - 309
IP  - 3
4099  - http://jpet.aspetjournals.org/content/309/3/1160.short
4100  - http://jpet.aspetjournals.org/content/309/3/1160.full
SO  - J Pharmacol Exp Ther2004 Jun 01; 309
AB  - The purpose of the present study was to determine whether the administration of an antagonist of aldosterone could prevent the fibrosis induced by an acute injection of isoprenaline. Male Wistar rats were submitted to one subcutaneous injection of isoprenaline (400 mg/kg) and were simultaneously treated with potassium canrenoate in drinking water (20 mg/kg/day) started 5 days before the injection of isoprenaline. Two months later, echocardiographic and hemodynamic measurements were performed. Then, the heart was prepared for morphometric histology and quantification of fibrosis in the left ventricle. Heart and left ventricular weights were increased significantly by isoprenaline. Potassium canrenoate attenuated this increase. The administration of isoprenaline increased significantly end diastolic diameter and end systolic volume compared with control. These changes were increased further with the addition of potassium canrenoate. In contrast, the fibrosis induced by isoprenaline was reduced significantly by potassium canrenoate at the three section levels. Potassium canrenoate attenuated the fibrosis but not the enhanced dilatation of the left ventricle induced by isoprenaline. The American Society for Pharmacology and Experimental Therapeutics